Clinical Trial Search

Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Objective Response Rate — 3 Participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Number of Participants With a Response — 17; 28; 8; 5 participants

Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV

Primary: Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 13…

Primary: Progression Free Survival (PFS) — 6.6 months

Primary: Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With…

Primary: Overall Response Rate — 38 percentage of participants

Primary: Recommended Phase II Dose (Phase I) — 20; 56 mg/m^2

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Overall Response Rate (ORR) As Measured By The Investigator — 35; 56.3; 60.0 Percentage of Participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants